$150M Public Offering Announced Days After Positive Phase 2 Data
SLN has more than doubled off its 52-week low of $4.19 on elevated volume (23× avg).
Summary
Silence Therapeutics is launching a $150 million underwritten public offering of ADSs, just hours after reporting blockbuster Phase 2 data for divesiran. The offering is separate from the $100 million ATM program activated in May and comes with a 15% underwriter option. With a market cap around $564 million, this raise is highly dilutive—roughly 27% of current market cap. The timing is aggressive: the company had $72.1 million in cash as of Q2 and just extended its runway into 2028, so the urgency suggests management wants to capitalize on the stock's post-data pop. The offering is being led by Jefferies, Morgan Stanley, Cantor, and William Blair. Pricing and final terms are pending, but the size alone will pressure the stock.
At the time of this announcement, SLN was trading at $15.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $564.5M. The 52-week trading range was $4.19 to $17.58. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.